一项评估mRNA基孔肯雅病毒疫苗在健康成人中安全性和免疫原性的1期随机安慰剂对照剂量递增研究
在美国基孔肯雅病毒非流行区开展的1期首次人体随机安慰剂对照剂量递增研究,纳入60名18-49岁健康成人,按3:1随机接受3个剂量组(25 μg、50 μg、100 μg)mRNA-1388或安慰剂,间隔28天肌肉注射2剂,随访至1年。结果显示mRNA-1388在各剂量水平安全性和反应原性良好,诱导持久体液免疫应答,中和抗体滴度呈剂量依赖性升高。
要点
- mRNA-1388在25、50、100 μg各剂量水平均显示良好的安全性和反应原性特征。
- 第2剂后28天中和抗体GMT(95%CI)分别为25 μg组6.2(5.1-7.6)、50 μg组53.8(26.8-108.1)、100 μg组92.8(43.6-197.6)、安慰剂组5.0(不可估计)。
- 接种后1年仍观察到持久体液应答,两个较高剂量组中和抗体水平仍高于安慰剂组。
核心结论
- mRNA-1388是首个针对基孔肯雅病毒的mRNA疫苗,在非流行区健康成人参与者中耐受性良好,并诱导了实质性和持久的中和抗体应答。
研究设计与样本
- 1期、首次人体、随机、安慰剂对照、剂量递增研究,于2017年7月至2019年3月在美国纳入18-49岁健康成人。
- 参与者按3:1随机接受间隔28天2次肌肉注射mRNA-1388(25 μg、50 μg、100 μg三个剂量组)或安慰剂,随访至1年。
- 共60名参与者随机分组并接受至少1次接种,54名(90%)完成研究。
主要发现
- mRNA-1388在所有剂量水平显示出良好的安全性和反应原性特征。
- 接种mRNA-1388诱导了实质性和持久的体液应答。
- 观察到中和抗体滴度呈剂量依赖性升高;第2剂后28天中和抗体GMT(95%CI)为:mRNA-1388 25 μg组6.2(5.1-7.6),mRNA-1388 50 μg组53.8(26.8-108.1),mRNA-1388 100 μg组92.8(43.6-197.6),安慰剂组5.0(不可估计)。
- 接种后至1年仍观察到持久体液应答,两个较高mRNA-1388剂量组的中和抗体水平仍高于安慰剂组。
- 基孔肯雅病毒结合抗体的发展与中和抗体观察到的趋势相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chikungunya, a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), causes a significant global health burden, and there is currently no approved vaccine to prevent chikungunya disease. In this study, the safety and immunogenicity of a CHIKV mRNA vaccine candidate (mRNA-1388) were evaluated in healthy participants in a CHIKV-nonendemic region. METHODS: This phase 1, first-in-human, randomized, placebo-controlled, dose-ranging study enrolled healthy adults (ages 18-49 years) between July 2017 and March 2019 in the United States. Participants were randomly assigned (3:1) to receive 2 intramuscular injections 28 days apart with mRNA-1388 in 3 dose-level groups (25 μg, 50 μg, and 100 μg) or placebo and were followed for up to 1 year. Safety (unsolicited adverse events [AEs]), tolerability (local and systemic reactogenicity; solicited AEs), and immunogenicity (geometric mean titers [GMTs] of CHIKV neutralizing and binding antibodies) of mRNA-1388 versus placebo were evaluated. RESULTS: Sixty participants were randomized and received ≥ 1 vaccination; 54 (90 %) completed the study. mRNA-1388 demonstrated favorable safety and reactogenicity profiles at all dose levels. Immunization with mRNA-1388 induced substantial and persistent humoral responses. Dose-dependent increases in neutralizing antibody titers were observed; GMTs (95 % confidence intervals [CIs]) at 28 days after dose 2 were 6.2 (5.1-7.6) for mRNA-1388 25 μg, 53.8 (26.8-108.1) for mRNA-1388 50 μg, 92.8 (43.6-197.6) for mRNA-1388 100 μg, and 5.0 (not estimable) for placebo. Persistent humoral responses were observed up to 1 year after vaccination and remained higher than placebo in the 2 higher mRNA-1388 dose groups. The development of CHIKV-binding antibodies followed a similar trend as that observed with neutralizing antibodies. CONCLUSIONS: mRNA-1388, the first mRNA vaccine against CHIKV, was well tolerated and elicited substantial and long-lasting neutralizing antibody responses in healthy adult participants in a nonendemic region. CLINICALTRIALS: gov: NCT03325075.
引用
- Shaw CA, August A, Bart S, et al. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine. 2023. PMID: 37210308. doi:10.1016/j.vaccine.2023.04.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。